NBC Securities Inc. Purchases 1,013 Shares of Eli Lilly and Company (NYSE:LLY)

NBC Securities Inc. lifted its position in Eli Lilly and Company (NYSE:LLY) by 27.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,770 shares of the company’s stock after buying an additional 1,013 shares during the quarter. NBC Securities Inc.’s holdings in Eli Lilly and Company were worth $3,711,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in LLY. Lipe & Dalton bought a new stake in Eli Lilly and Company during the fourth quarter worth approximately $26,000. Tidemark LLC bought a new stake in Eli Lilly and Company during the fourth quarter worth approximately $29,000. Core Wealth Advisors Inc. boosted its position in Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares during the period. Optiver Holding B.V. acquired a new position in shares of Eli Lilly and Company during the third quarter worth approximately $36,000. Finally, Frank Rimerman Advisors LLC acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $37,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $891.46 on Thursday. The business’s fifty day moving average price is $793.39 and its two-hundred day moving average price is $724.73. Eli Lilly and Company has a fifty-two week low of $434.34 and a fifty-two week high of $894.87. The stock has a market capitalization of $847.25 billion, a price-to-earnings ratio of 131.29, a price-to-earnings-growth ratio of 1.94 and a beta of 0.36. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same period in the prior year, the business posted $1.62 earnings per share. The business’s revenue was up 26.0% compared to the same quarter last year. As a group, analysts predict that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 10th. Stockholders of record on Thursday, May 16th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.58%. The ex-dividend date of this dividend was Wednesday, May 15th. Eli Lilly and Company’s payout ratio is presently 76.58%.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research analyst reports. Truist Financial upped their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a report on Monday. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. BMO Capital Markets upped their price target on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a report on Wednesday, May 1st. Finally, Bank of America upped their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $787.53.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 92,563 shares of the stock in a transaction on Friday, May 24th. The stock was sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the sale, the insider now owns 98,556,247 shares in the company, valued at $79,752,700,634.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the sale, the chief accounting officer now owns 7,130 shares in the company, valued at $5,842,821.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 92,563 shares of the stock in a transaction on Friday, May 24th. The stock was sold at an average price of $809.21, for a total value of $74,902,905.23. Following the sale, the insider now owns 98,556,247 shares in the company, valued at approximately $79,752,700,634.87. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 762,804 shares of company stock worth $648,109,138. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.